Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.09M
Average 4.03M
AKBA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Akebia Therapeutics, Inc.NASDAQ: AKBA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $328K rose 4.5% year over year, ahead of the -96.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at -67.7% a year.
Context
- Depreciation & amortization amounted to 0.5% of revenue in FY2025, down 22.9 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +4.5% holds above the trailing-twelve-month pace of -96.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.27M USD
- Year-over-year change
- -96.6%
- 4-year CAGR
- -56.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.27M | -96.6% |
| FY2024 | 2024-12-31 | 37.5M | -10.4% |
| FY2023 | 2023-12-31 | 41.85M | +11.0% |
| FY2022 | 2022-12-31 | 37.7M | +4.3% |
| FY2021 | 2021-12-31 | 36.13M | — |
Depreciation & Amortization vs competitors
How AKBA compares with its peers on the latest reported figures
- AKBA's LTM Mar 2026 depreciation & amortization of $1.28M is the 4th largest of the 10 companies compared; the peer median is $892K.
- Its year-over-year change of -96.1% is the 8th highest of 9, against a peer median of +5.0%.
- Depreciation & amortization amounts to 0.6% of revenue for AKBA, versus a peer median of 1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.93M | +15.5% | +25.3% | 9.0% | |
| LTM Mar 2026 | $2.77M | -57.2% | +62.5% | 2.3% | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
| LTM Mar 2026 | $1.28M | -96.1% | -67.7% | 0.6% | |
| LTM Dec 2025 | $1.19M | — | — | 1.0% | |
| LTM Mar 2026 | $892K | -74.4% | -39.1% | 1.6% | |
| LTM Mar 2026 | $856K | +258.2% | +6.4% | 1.5% | |
| LTM Mar 2026 | $481K | +11.1% | -33.4% | — | |
| LTM Mar 2026 | $468K | -128.3% | — | — | |
| LTM Mar 2026 | $112K | +33.3% | -34.1% | — | |
| Peer median (excluding AKBA) | $892K | +5.0% | +6.4% | 1.5% | |
Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (282.02M) | (92.56M) | (51.93M) | (69.41M) | (5.35M) |
| Depreciation & Amortization | 36.13M | 37.7M | 41.85M | 37.5M | 1.27M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.74M | 17.85M | 9.32M | 7.78M | 11.28M |
| Change in Working Capital | (105.61M) | (1.44M) | (20.73M) | (39.68M) | 16.47M |
| Accounts Receivables | (24.03M) | 11.7M | 994K | 4.05M | (14.14M) |
| Inventory | (24.95M) | 19.79M | (2.54M) | (28.4M) | (23.13M) |
| Accounts Payables | (11.74M) | 1.5M | (5.24M) | (1.36M) | 3.08M |
| Other Working Capital | (44.9M) | (34.42M) | (13.94M) | (13.96M) | 50.66M |
| Other Non-Cash Items | 98.54M | (34.7M) | (1.9M) | 23.15M | 44.31M |
| Operating Cash Flow | (252.97M) | (73.15M) | (23.38M) | (40.66M) | 67.99M |
| Capital Expenditures | (59K) | (114K) | 0 | (33K) | (291K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 40M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (7.93M) |
| Investing Cash Flow | 39.94M | (114K) | 0 | (33K) | (7.93M) |
| Debt Repayment | 44.78M | (33M) | (32M) | 7.9M | 4.63M |
| Common Stock Issued | 88.95M | 7.53M | 6.79M | 42.65M | 68.36M |
| Common Stock Repurchased | 0 | 0 | 0 | (1.27M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 40.07M | 1K | 385K | (63K) |
| Financing Cash Flow | 133.73M | 14.6M | (25.21M) | 49.66M | 72.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (79.29M) | (58.67M) | (48.59M) | 8.97M | 132.99M |
| Free Cash Flow | (253.02M) | (73.27M) | (23.38M) | (40.69M) | 67.99M |
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.